Abstract: This disclosure describes hardware for microfluidic chips and an associated platform for facilitating operation of one or more microfluidic chips. The microfluidic chips described herein are designed for supporting multiple different tissue types, including kidney tissue, liver tissue, adipose cells, and so forth. Chip geometry facilities fluid flow through one or more channels of the chip with a particular flow rate. For example, shear forces are reduced where needed to ensure proper flow rate of fluid in the channels. The chamber geometry and the geometry of the channels ensures that a desired amount of oxygen is delivered to sample cells or tissues in a controlled manner.

Abstract: A microphysiological system (MPS) includes at least one first inlet for receiving a fluid medium. The MPS includes a brain module comprising brain tissue. The MPS includes a blood-brain-barrier (BBB) module comprising BBB tissue, the BBB module configured to receive the fluid medium. The MPS includes a crosstalk channel between the brain module and the BBB module, the crosstalk channel configured to promote a bidirectional crosstalk between the brain tissue and the BBB tissue in response to receiving the fluid medium at the BBB module. The MPS is configured for treating the brain tissue and the BBB tissue with a drug or a combination of drugs to determine a phenotypic effect and a transcriptomic effect of the drug. A drug perturbation is related to the phenotypic effect and the transcriptomic effect based on kinetic optimization.

Abstract: A microphysiological system (MPS) includes at least one first inlet for receiving a fluid medium. The MPS includes a brain module comprising brain tissue. The MPS includes a blood-brain-barrier (BBB) module comprising BBB tissue, the BBB module configured to receive the fluid medium. The MPS includes a crosstalk channel between the brain module and the BBB module, the crosstalk channel configured to promote a bidirectional crosstalk between the brain tissue and the BBB tissue in response to receiving the fluid medium at the BBB module. The MPS is configured for treating the brain tissue and the BBB tissue with a drug or a combination of drugs to determine a phenotypic effect and a transcriptomic effect of the drug. A drug perturbation is related to the phenotypic effect and the transcriptomic effect based on kinetic optimization.

Abstract: This disclosure describes hardware for microfluidic chips and an associated support module for facilitating operation of one or more microfluidic chips. The microfluidic chips described herein are designed for supporting multiple different tissue types, including kidney tissue, liver tissue, adipose cells, and so forth. Chip geometry facilities fluid flow through one or more channels of the chip with a particular flow rate. For example, shear forces are reduced where needed to ensure proper flow rate of fluid in the channels. The chamber geometry and the geometry of the channels ensures that a desired amount of oxygen is delivered to sample cells or tissues in a controlled manner.

Abstract: Microfluidic platforms including multiple microphysiological systems. At least one of the platforms include: at least one inlet; a plurality of organ constructs, each organ construct of the plurality of organ constructs being sized relative to other organ constructs of the plurality of organ constructs based on at least one predetermined human pharmacokinetic (PK) parameter; and a plurality of channels, each channel of the plurality of channels causing an organ construct of the plurality of organ constructs to be in fluidic communication with at least one other organ construct of the plurality of organ constructs.

Abstract: Microfluidic platforms including multiple microphysiological systems. At least one of the platforms include: at least one inlet; a plurality of organ constructs, each organ construct of the plurality of organ constructs being sized relative to other organ constructs of the plurality of organ constructs based on at least one predetermined human pharmacokinetic (PK) parameter; and a plurality of channels, each channel of the plurality of channels causing an organ construct of the plurality of organ constructs to be in fluidic communication with at least one other organ construct of the plurality of organ constructs.

Abstract: A method for developing stratified medicine for nonalcoholic fatty liver disease (NAFLD includes obtaining a microphysiological system (MPS) comprising a liver tissue cytoarchitecture, adipose tissue, or both. The method includes inducing metabolic dysfunction representing NAFLD in the liver or adipose tissue of the MPS. The method includes generating, based on inducing the metabolic dysfunction, transcriptomics data for the MPS. The method includes applying a drug to the MPS using a dosing regimen. The method includes monitoring changes in the transcriptomics data based on applying the drug. The method includes generating a model relating the changes in the transcriptomics data to the dosing regimen of the drug.

Abstract: A microphysiological system (MPS) includes at least one first inlet for receiving a fluid medium. The MPS includes a brain module comprising brain tissue. The MPS includes a blood-brain-barrier (BBB) module comprising BBB tissue, the BBB module configured to receive the fluid medium. The MPS includes a crosstalk channel between the brain module and the BBB module, the crosstalk channel configured to promote a bidirectional crosstalk between the brain tissue and the BBB tissue in response to receiving the fluid medium at the BBB module. The MPS is configured for treating the brain tissue and the BBB tissue with a drug or a combination of drugs to determine a phenotypic effect and a transcriptomic effect of the drug. A drug perturbation is related to the phenotypic effect and the transcriptomic effect based on kinetic optimization.